SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: Expert consensus statement by KASID

The Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases (KASID)

Research output: Contribution to journalArticlepeer-review

Abstract

Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.

Original languageEnglish
Pages (from-to)171-183
Number of pages13
JournalIntestinal Research
Volume20
Issue number2
DOIs
StatePublished - 2022

Keywords

  • COVID-19
  • COVID-19 vaccines
  • Inflammatory bowel disease
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: Expert consensus statement by KASID'. Together they form a unique fingerprint.

Cite this